Trial Profile

Safety and Immunogenicity of Fluzone Quadrivalent, Flublok Quadrivalent, and Fluzone High-Dose, Influenza Vaccines, 2018-2019 Formulations

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 17 Jan 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Influenza virus RIV4 vaccine-(FluBlok Quadrivalent) (Primary) ; Influenza virus vaccine (Primary) ; Influenza virus vaccine (Primary)
Indications Influenza virus infections
Focus Adverse reactions; Pharmacodynamics
Sponsors Sanofi Pasteur

Most Recent Events

10 Dec 2018 Status changed from recruiting to completed.
26 Sep 2018 Planned number of patients changed from 240 to 120.
26 Sep 2018 Status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com